Cardiologist (M.D Ph.D. FESC FEACVI FHFA) at MST @ziekenhuisMST #CVImaging #HeartFailure and Researcher at University of Twente @UTwente #digital #eHealth #AI
The Netherlands
Joined November 2009
- Tweets2.5K
- Following4.3K
- Followers1.5K
- Likes2.9K
Pinned Tweet
Presentation and publications #latebreaking
The strategy was effective to 📈GDMT
#ESCCongress
@escardio @Rafavidalperez @BruiningNico @HFA_President
@nature @WilfriedMullens @jozinetm @HanCardiomd @gcfmd @SJGreene_md @hvanspall @VDelgadoGarcia @CharlesFauvel
@slumberbell
Mark Schuuring retweeted
Challenges of aortic valve stenosis #VHD scenarios: how to get the diagnosis right with @EACVIPresident
🗓️Thursday, 16 October 2025, ⏲️ 18:00 to 19:00 CEST #Webinar
Organiser: European Association of Cardiovascular Imaging (EACVI)
Register now: 👉esc365.escardio.org/event/20…
Mark Schuuring retweeted
🔥 New in @NatureMedicine
How do you communicate lifetime benefits expected with HFpEF therapies?
New data from 3 RCTs (#DELIVER #FINEARTS #PARAGON) estimate up to *5 years* of event-free survival w combination Rx
#GDMT for HFpEF has finally arrived!
🔗nature.com/articles/s41591-0…
Mark Schuuring retweeted
Development of an Innovative Pipeline With Fusion, Digital Planning, and Three‐Dimensional Printing to Improve Mitral Valve Interventional Care - Man - 2025 - Echocardiography - Wiley Online Library onlinelibrary.wiley.com/doi/…
Great work @ankeetbhatt !
Thrilled to present #LBCT @escardio #HFA2025 on early readmissions in #FINEARTSHF. Favorable trends with ⏬30-day HF/CV hosp w/ early implementation of #fineranone in currently/recently hospitalized HFmrEF/HFpEF. #SimPub now in @JCardFail! 🙏🏽 @mvaduganathan @scottdsolomon & team
Mark Schuuring retweeted
📢 Results of our EASY-STOP study now presented #LBCT at #HeartFailure2025! A thread 🧵
1/ 🚀 First study to evaluate home-based #UNa using a POC sensor to guide loop diuretic downtitration in chronic #HeartFailure patients. #Cardiology #FOAMed
Mark Schuuring retweeted
🚨 Excited to share our work on #AI #DASSi phenotyping of #AS on 2D #EchoFirst: a low-cost surrogate for multimodality imaging in AS trials
A fun collaboration between @cards_lab @rohan_khera & @EdinburghUni (Marc Dweck, @neiljcraig et al)
🔗 Preprint + 🧵below #ACC25
Mark Schuuring retweeted
For all the passionate professionals for cardiovascular imaging, this is your opportunity to mingle with, to network with and to learn from a large community with expertise on 4 modalities. Take advantage and join us! escardio.org/Congresses-Even…
@iCorGTrias @imagen_sec
Join Us at the #EACVI 2025 Conference in Vienna!
📅 December 11-13, 2025
📍 Vienna, Austria
Experience the future of cardiovascular imaging as #EuroEcho #ICNCCT & #EuroCMR come together under one roof at the #EACVI 2025 Conference!
🔹 Cutting-edge research
🔹 Expert-led sessions
🔹 Multimodality imaging insights
🔹 Networking with global leaders
Don’t miss this unparalleled opportunity to advance your knowledge and connect with the best in the field!
escardio.org/Congresses-Even…
@VDelgadoGarcia @s_e_petersen @denisamuraru @NAjmoneMarsan @anatimoteo46040 @LunaGargani @PezelT @carpenter_jp @rmanka_ @Sarah_Moharem
Mark Schuuring retweeted
Proud to be part of this huge effort to synthesize the trial data with IV iron in HF with ID
nature.com/articles/s41591-0…
Mark Schuuring retweeted
Using #ArtificialIntelligence to calculate the heart’s biological age through #ECG data predicts increased risk of mortality and #cardiovascular events 👇
#AI #HeartHealth #EHRA2025 #EHRA_ESC
Mark Schuuring retweeted
New from #ACC25: Dr. Nuccia Morici & colleagues report the results of ALTSHOCK-2, finding that early implantation of IABP does *not* reduce 60-day mortality in #heartfailure-related cardiogenic shock
#JACC 🧵 (1/4)
Mark Schuuring retweeted
Thrilled to share at #EHRA2025 the Choice-ICD study. An APP co-designed by patients @pumpinghearts @HFWarriorNI1 & clinical experts @BelfastTrust & GJNH, funded by @TheBHF. Ready to start UK testing @UlsterUniSoNP @QUBSONM
Mark Schuuring retweeted
Would you discharge an eligible patient with HFrEF w/o one or more disease-modifying, life-saving medications?
How about if you knew the odds are 7-15 fold against them ever being initiated as an outpatient?
How about if you were contributing to 100K preventable ☠️s per year?
Mark Schuuring retweeted
What is the likelihood that this RCT will meet its primary endpoint?
A Digital Platform to Optimize Guideline Directed Heart Failure Therapy: Rationale and Design of the AIM-POWER Trial - Journal of Cardiac Failure onlinejcf.com/article/S1071-…
@JCardFail @robmentz @texhern @HFSA
Mark Schuuring retweeted
✅ When RCT protocol directed, a large proportion of patients with HFrEF are treated with quadruple GDMT
❌ In clinical practice, when left to clinician discretion, it is < 1 in 10 of patients eligible that are actually treated, even in settings with no cost/access barriers
Mark Schuuring retweeted
HFmrEF/HFpEF can’t wait
Rx the 3 🏛️
SGLTi + nsMRA + GLP-1 RA (if obesity)
The optimal strategy is simultaneous or rapid sequence initiation to all eligible patients, without delay
@gcfmd @JavedButler1 @DCRINews @JAMACardio
jamanetwork.com/journals/jam……
Mark Schuuring retweeted
The role of multi-modality imaging for the assessment of left atrium and #LAA: a clinical consensus statement of the @EACVIPresident & @EHRAPresident of @escardio by @EHJCVIEiC
@leylaelifsade et al. ☑️shorturl.at/ukSeX
@denisamuraru @EHJIMPEiC @JGrapsa @BakhshiHooman
Mark Schuuring retweeted
The clinical benefits of simultaneous or rapid initiation outweigh the potential risks in HFmrEF/HFpEF
Simultaneous or Rapid Initiation of Combination Therapy for Heart Failure With Preserved Ejection Fraction jamanetwork.com/journals/jam…
@SJGreene_md @JavedButler1 @JAMACardio
Mark Schuuring retweeted
What for Worsening Heart Failure Events jamanetwork.com/journals/jam…
@texhern @NMHheartdoc @JAMACardio @JavedButler1 @SJGreene_md @mvaduganathan @scottdsolomon @UoGHeartFailure
Mark Schuuring retweeted
💡How to make #CVImaging research truly impact patient care? Raise the bar on precision & clinical relevance!🫀Check out the #EACVI statement🔗 doi.org/10.1093/ehjci/jeae23… by💫 @denisamuraru @gpontone1 @RJurcut @JulienMagne @DonalErwan @Ivan_Echocardio @MariannaFonta11 @ElenaGalli10 @bwmichalski , @PezelT @ThorEdvardsen @s_e_petersen @Cosyns @Ph_Bertrand @VDelgadoGarcia @KristinaHaugaa @DaniloNeglia & team published at #EHJCVI
@EACVIPresident @EHJIMPEiC @alessia_gimelli @JGrapsa @EZancanaroMD @BenekiEirini @BakhshiHooman @HanCardiomd @ProtonotariosA @ESC_Journals @CTECresearch @ESC_Lavinia @AugustinCoisne @rmanka_ @Alkadhi_rad @SCMRorg @ErsozluSara @saramoscatelli7 @andgiannopmd @mjschuuring @rafavidalperez @mmamas1973 @rbcasado @ESC_Camille 🌠#CardioEd #PatientCare
Goodmorning #EHJCVI
@ShehabAnwer provides an excellent ‘take home messages ‘ video on “How to conduct clinical research in CVI - an EACVI statement’ by @denisamuraru and colleagues ➡️ academic.oup.com/ehjcimaging… @ESC_Journals @ShehabAnwer @EACVIPresident @bernhard_gerber @JGrapsa
Mark Schuuring retweeted
Patients with suspected heart failure and elevated NT-proBNP in outpatient care had high mortality and morbidity in the weeks after presentation. Read the results of the REVOLUTION HF study just published in #EHJ 👉 bit.ly/3CSmnns @RoccoMontone @ehj_ed #heartfailure
